MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- BIOCON
- BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8%
BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8%
Fri, 26 Apr
BIOCON has announced its results for the quarter ended March 2019. Here is a detailed performance review of the same:
BIOCON Quarterly Financials
| No. of Mths Qtr. Ending | 3 Mar-18* | 3 Dec-18* | 3 Mar-19* | QoQ Change | YoY Change | |
|---|---|---|---|---|---|---|
| Net Sales | Rs m | 11,695 | 15,408 | 7,639 | -50.4% | -34.7% |
| Other income | Rs m | 675 | 256 | 139 | -45.7% | -79.4% |
| Turnover | Rs m | 12,370 | 15,664 | 7,778 | -50.3% | -37.1% |
| Expenses | Rs m | 9,365 | 11,601 | 6,654 | -42.6% | -28.9% |
| Gross profit | Rs m | 2,381 | 3,865 | 985 | -74.5% | -58.6% |
| Depreciation | Rs m | 953 | 1,167 | 375 | -67.9% | -60.7% |
| Interest | Rs m | 169 | 186 | 6 | -96.8% | -96.4% |
| Profit before tax | Rs m | 1,934 | 2,768 | 743 | -73.2% | -61.6% |
| Tax | Rs m | 407 | 461 | 38 | -91.8% | -90.7% |
| Profit after tax | Rs m | 1,527 | 2,307 | 705 | -69.4% | -53.8% |
| Gross profit margin | % | 20.4 | 25.1 | 12.9 | ||
| Effective tax rate | % | 21.0 | 16.7 | 5.1 | ||
| Net profit margin | % | 12.3 | 14.7 | 9.1 |
Interim results exclude extraordinary / exceptional items
Year-on-Year Performance:
- The company's operating income during the quarter fell 34.7% on a year-on-year (YoY) basis. The expenses were down by 28.9% YoY during the same period.
- The company's operating profit declined by 58.6% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 12.9% in 4QFY19 as against 20.4% in 4QFY18.
- Depreciation charges declined by 60.7% and finance costs declined by 96.4% YoY, respectively.
- Other income declined by 79.4% YoY during the quarter.
- Net profit for the quarter declined by 53.8% YoY. Net profit margins during the quarter declined from 12.3% in 4QFY18 to 9.1% in 4QFY19.
Quarter-on-Quarter Performance:
- The company's operating income during the quarter fell 50.4% on a quarter-on-quarter (QoQ) basis. The expenses were down by 42.6% QoQ during the same period.
- The company's operating profit declined by 74.5% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 12.9% in 4QFY19 as against 25.1% in 3QFY18.
- Net profit for the quarter declined by 69.4% QoQ, while net profit margins declined from 14.7% in 3QFY18 to 9.1% in 4QFY19.
To see how BIOCON has performed over the last eight quarters, please visit here.
BIOCON Share Price Performance
Over the last one year, BIOCON share price has moved up from Rs 663.3 to Rs 619.9, registering a Loss of Rs 43.4 or around 6.5%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,464.7 (up 0.2%). Over the last one year it has moved up from 13,930.8 to 14,464.7, a gain of 534 points (up 3.8%).
Overall, the S&P BSE SENSEX is up 13.2% over the year.
Current Valuations
At the current price of Rs 619.9, the price to earnings (P/E) ratio of BIOCON stands at 45.5 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 7.2 times.
|
| |
Related Views on News
BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)
Jan 28, 2019 | Updated on Jan 28, 2019For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)
Nov 9, 2018 | Updated on Nov 9, 2018For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)
Jun 23, 2017Net Profit lower due to exceptional items in the previous year.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)
Jun 13, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)
Jun 11, 2019One chart that predicted the NBFC crisis back in 2016.
Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)
Jun 12, 2019This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.
Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)
Jun 10, 2019The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.
Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)
Jun 14, 2019Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.
More|
| |
BIOCON SHARE PRICE
Jun 20, 2019 03:35 PM
TRACK BIOCON
- Track your investment in BIOCON with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON
BIOCON - ADCOCK INGRAM COMPARISON
COMPARE BIOCON WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster requests your view! Post a comment on "BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!